Gene
CNRIP1
| Entrez Gene ID | 25927 (See on NCBI) |
| Description | cannabinoid receptor interacting protein 1 |
| Gene Synonyms | C2orf32, CRIP1 |
| Node consisting of this Gene | CNRIP1 C2orf32 |
Networks including this gene
| GSE14095_top8000 - GSE14095 - SiGN-BN NNSR | Gene expression signature and the prediction of liver metastasis in colorectal cancer by DNA microarray |
| GSE10245_top8000 - GSE10245 - SiGN-BN NNSR | Gene expression differences between adenocarcinoma and squamous cell carcinoma in human NSCLC |
| GSE10358_top8000 - GSE10358 - SiGN-BN NNSR | Discovery and validation of expression data for the Genomics of Acute Myeloid Leukemia Program at Washington University. |
| GSE10445_top8000 - GSE10445 - SiGN-BN NNSR | MERLION LUNG CANCER STUDY |
| GSE10780_top8000 - GSE10780 - SiGN-BN NNSR | Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue |
| GSE10810_top8000 - GSE10810 - SiGN-BN NNSR | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
| GSE10843_top8000 - GSE10843 - SiGN-BN NNSR | mRNA Cancer Cell Line Profiles |
| GSE10890_top8000 - GSE10890 - SiGN-BN NNSR | mRNA Breast Cancer Cell Line Profiles |
| GSE10927_top8000 - GSE10927 - SiGN-BN NNSR | Human adrenocortical carcinomas (33), adenomas (22), and normal adrenal cortex (10), on Affymetrix HG_U133_plus_2 arrays |
| GSE10972_top8000 - GSE10972 - SiGN-BN NNSR | Colon cancer |
| GSE11135_top8000 - GSE11135 - SiGN-BN NNSR | The MILE (Microarray Innovations In LEukemia) study pre-phase |
| GSE11869_top8000 - GSE11869 - SiGN-BN NNSR | The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. |
| GSE12195_top8000 - GSE12195 - SiGN-BN NNSR | Mutations of multiple genes deregulate the NF-kB pathway in diffuse large B cell lymphoma |
| GSE12453_top8000 - GSE12453 - SiGN-BN NNSR | Origin and pathogenesis of lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis |
| GSE12777_top8000 - GSE12777 - SiGN-BN NNSR | Gene expression profiling of 51 human breast cancer cell lines |
| GSE12790_top8000 - GSE12790 - SiGN-BN NNSR | Gene expression profiling of human breast cancers and cancer cell lines |
| GSE13255_top8000 - GSE13255 - SiGN-BN NNSR | Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with NonSmall Cell Lung Cancer. |
| GSE13507_top8000 - GSE13507 - SiGN-BN NNSR | Predective Value of Prognosis-Related Gene Expression Study in Primary Bladder Cancer |
| GSE13598_top8000 - GSE13598 - SiGN-BN NNSR | mRNA expression of 131 cancer cell lines |
| GSE13898_top8000 - GSE13898 - SiGN-BN NNSR | Robust prognostic biomarkers for EAC identified by systems-level characterization of tumor transcriptome |
| GSE14206_top8000 - GSE14206 - SiGN-BN NNSR | Analysis of ETS gene expression patterns uncovers novel ETS mediated gene silencing pathways in prostate cancers |
| GSE14315_top8000 - GSE14315 - SiGN-BN NNSR | Effects of demethylation on lung cancer cell lines |
| GSE14879_top8000 - GSE14879 - SiGN-BN NNSR | Gene expression study of anaplastic large cell lymphomas: cellular origin, pathogenesis and relation to Hodgkin lymphoma |
| GSE15329_top8000 - GSE15329 - SiGN-BN NNSR | Gene expression profiling of human non-Hodgkins lymphoma (NHL) cell lines |
| GSE15395_top8000 - GSE15395 - SiGN-BN NNSR | HCT116 tumor cells treated with a CDK inhibitor |
| GSE15396_top8000 - GSE15396 - SiGN-BN NNSR | Peripheral blood mononuclear, DU145, and HCT116 cells treated with a CDK inhibitor |
| GSE15471_top8000 - GSE15471 - SiGN-BN NNSR | Whole-Tissue Gene Expression Study of Pancreatic Ductal Adenocarcinoma |
| GSE16120_top8000 - GSE16120 - SiGN-BN NNSR | Gene profiling, mutations and expression of epidermal growth factor receptor in androgen-dependent prostate cancer |
| GSE16382_top8000 - GSE16382 - SiGN-BN NNSR | Expression data from complex genetic sarcomas |
| GSE16391_top8000 - GSE16391 - SiGN-BN NNSR | GGI: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial |
| GSE16446_top8000 - GSE16446 - SiGN-BN NNSR | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| GSE16455_top8000 - GSE16455 - SiGN-BN NNSR | Indolent MCL identified by genomic and gene expression profiling |
| GSE16515_top8000 - GSE16515 - SiGN-BN NNSR | Expression data from Mayo Clinic Pancreatic Tumor and Normal samples |
| GSE16581_top8000 - GSE16581 - SiGN-BN NNSR | Genomic landscape of meningiomas: gene expression |
| GSE16757_top8000 - GSE16757 - SiGN-BN NNSR | Gene expression study in hepatocellular carcinoma |
| GSE16987_top8000 - GSE16987 - SiGN-BN NNSR | A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis |
| GSE17536_top8000 - GSE17536 - SiGN-BN NNSR | Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (Moffitt Samples) |
| GSE17537_top8000 - GSE17537 - SiGN-BN NNSR | Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (VMC Samples) |
| GSE17913_top8000 - GSE17913 - SiGN-BN NNSR | Effects of Cigarette Smoke on the Human Oral Mucosal Transcriptome |
| GSE17920_top8000 - GSE17920 - SiGN-BN NNSR | Expression data of diagnostic biopsy samples from Hodgkin lymphoma patients |
| GSE17951_top8000 - GSE17951 - SiGN-BN NNSR | Gene expression analysis of prostate cancer samples using Affymetrix U133Plus2 array |
| GSE18088_top8000 - GSE18088 - SiGN-BN NNSR | Correlation of molecular profiles and clinical outcome of stage UICC II colon cancer patients |
| GSE18105_top8000 - GSE18105 - SiGN-BN NNSR | Stage II and stage III colorectal cancer |
| GSE18520_top8000 - GSE18520 - SiGN-BN NNSR | Whole-genome oligonucleotide expression analysis of papillary serous ovarian adenocarcinomas |
| GSE18521_top8000 - GSE18521 - SiGN-BN NNSR | A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: MAGP2 |
| GSE18728_top8000 - GSE18728 - SiGN-BN NNSR | Expression data from human breast cancers pre and post chemothrapy |
| GSE18842_top8000 - GSE18842 - SiGN-BN NNSR | Gene expression analysis of human lung cancer and control samples |
| GSE18864_top8000 - GSE18864 - SiGN-BN NNSR | Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients |
| GSE19069_top8000 - GSE19069 - SiGN-BN NNSR | Molecular signatures in peripheral T-cell lymphoma (PTCL) |
| GSE19188_top8000 - GSE19188 - SiGN-BN NNSR | Expression data for early stage NSCLC |
| GSE19274_top8000 - GSE19274 - SiGN-BN NNSR | Expression profiling in Neuroblastoma Primary tumors and Cell lines |
| GSE19784_top8000 - GSE19784 - SiGN-BN NNSR | Gene expression profiling of multiple myeloma patients included in the HOVON65/GMMG-HD4 trial |
| GSE19804_top8000 - GSE19804 - SiGN-BN NNSR | Genome-wide screening of transcriptional modulation in non-smoking female lung cancer in Taiwan |
| GSE20842_top8000 - GSE20842 - SiGN-BN NNSR | Mutated KRAS induces overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas |
| GSE20916_top8000 - GSE20916 - SiGN-BN NNSR | Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data |
| GSE21050_top8000 - GSE21050 - SiGN-BN NNSR | Expression data from Complex genetics sarcomas (cohort 1 and 2) |
| GSE21501_top8000 - GSE21501 - SiGN-BN NNSR | A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma |
| GSE21510_top8000 - GSE21510 - SiGN-BN NNSR | Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer |
| GSE21653_top8000 - GSE21653 - SiGN-BN NNSR | A gene expression signature identifies two prognostic subgroups of basal breast cancer |
| GSE22138_top8000 - GSE22138 - SiGN-BN NNSR | Expression Data from Uveal Melanoma primary tumors. |
| GSE22541_top8000 - GSE22541 - SiGN-BN NNSR | Expression data from pulmonary metastases and primary tumors of clear-cell renal cell carcinoma (ccRCC) with different disease-free survivals |
| GSE23177_top8000 - GSE23177 - SiGN-BN NNSR | Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. |
| GSE23553_top8000 - GSE23553 - SiGN-BN NNSR | Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines. |
| GSE23593_top8000 - GSE23593 - SiGN-BN NNSR | Intratumor Heterogeneity and Precision of Microarray-Based Predictors of Breast Cancer Biology and Clinical Outcome |
| GSE23806_top8000 - GSE23806 - SiGN-BN NNSR | Expression data of glioblastoma stem-like (GS) cell lines, conventional glioma cell lines and primary tumors |
| GSE23878_top8000 - GSE23878 - SiGN-BN NNSR | Genome Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy |
| GSE23980_top8000 - GSE23980 - SiGN-BN NNSR | Expression data from human soft tissue sarcomas with complex genomics |
| GSE23991_top8000 - GSE23991 - SiGN-BN NNSR | Effect of zebularine on primary human liver cancer cell lines |
| GSE24080_top8000 - GSE24080 - SiGN-BN NNSR | MAQC-II Project: Multiple myeloma (MM) data set |
| GSE26599_top8000 - GSE26599 - SiGN-BN NNSR | Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2 overexpressing human mammary epithelial cell lines |
| GSE26639_top8000 - GSE26639 - SiGN-BN NNSR | Expression Data from 226 patients of the REMAGUS02 trial |
| GSE26906_top8000 - GSE26906 - SiGN-BN NNSR | APC colon stage II |
| GSE27480_top8000 - GSE27480 - SiGN-BN NNSR | Gene-expression analysis of Oncostatin-M (OSM) signalling in cervical squamous cell carcinomas over-expressing the Oncostatin-M receptor (OSMR) |
| GSE27562_top8000 - GSE27562 - SiGN-BN NNSR | Expression data from human PBMCs from breast cancer patients and controls |
| GSE28821_top8000 - GSE28821 - SiGN-BN NNSR | Laser-capture microdissected invasive micropapillary carcinomas of the breast |
| GSE29288_top8000 - GSE29288 - SiGN-BN NNSR | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Agilent WG platform) |
| GSE30240_top8000 - GSE30240 - SiGN-BN NNSR | Expression data from 5 human cell lines exposed to IR (5 Gy) |
| GSE30784_top8000 - GSE30784 - SiGN-BN NNSR | Gene expression profiling of oral squamous cell carcinoma (OSCC) |
| GSE31279_top8000 - GSE31279 - SiGN-BN NNSR | Decoding differentially regulated epithelial and stromal pathways in colorectal cancer |
| GSE31548_top8000 - GSE31548 - SiGN-BN NNSR | MSKCC-B Primary Lung Cancer Specimens |
| GSE31552_top8000 - GSE31552 - SiGN-BN NNSR | Expression Data from human Lung tissue of Patients with Non Small Cell Lung Cancer (NSCLC) |
| GSE32448_top8000 - GSE32448 - SiGN-BN NNSR | CPDR tumor-benign 80 genechip dataset |
| GSE32474_top8000 - GSE32474 - SiGN-BN NNSR | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Affymetrix U133 Plus 2.0) |
| GSE4459_top8000 - GSE4459 - SiGN-BN NNSR | Gene expression signature and the prediction of lymph node metastases |
| GSE4554_top8000 - GSE4554 - SiGN-BN NNSR | Gene expression signature of colorectal cancer with microsatellite instability. |
| GSE5206_top8000 - GSE5206 - SiGN-BN NNSR | Large-scale deployment of embryonic gene programming in human and murine colon cancer: a new target for intervention. |
| GSE5900_top8000 - GSE5900 - SiGN-BN NNSR | Gene Expression of Bone Marrow Plasma Cells from Healthy Donors (N=22), MGUS (N=44), and Smoldering Myeloma (N=12) |
| GSE6338_top8000 - GSE6338 - SiGN-BN NNSR | Gene expression analysis of Peripheral T-cell Lymphoma/Unspecified |
| GSE6465_top8000 - GSE6465 - SiGN-BN NNSR | Expression data of Hepatocellular Carcinoma |
| GSE6764_top8000 - GSE6764 - SiGN-BN NNSR | Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma |
| GSE7604_top8000 - GSE7604 - SiGN-BN NNSR | Human Colon tumor vs Normal Human DNA |
| GSE7606_top8000 - GSE7606 - SiGN-BN NNSR | Human Melanoma vs Normal Human DNA |
| GSE7696_top8000 - GSE7696 - SiGN-BN NNSR | Glioblastoma from a homogenous cohort of patients treated within clinical trial |
| GSE8139_top8000 - GSE8139 - SiGN-BN NNSR | Expression data from MCF7/HER2-18 xenografts |
| GSE8141_top8000 - GSE8141 - SiGN-BN NNSR | Expression data from MCF7 wt and MCF7/HER2-18 xenografts |
| GSE8332_top8000 - GSE8332 - SiGN-BN NNSR | Death receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL |
| GSE8894_top8000 - GSE8894 - SiGN-BN NNSR | Prediction of Recurrence-Free Survival in Postoperative NSCLC Patients—a Useful Prospective Clinical Practice |
| GSE9195_top8000 - GSE9195 - SiGN-BN NNSR | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
(98 networks)
